Senate advances RFK Jr.’s HHS bid; NIH deputy abruptly resigns; FDA approves SpringWorks’ genetic disorder drug.

Royalty Pharma is giving Biogen $250 million for its lupus treatment litifilimab, which is currently in Phase 3 development ...

Total headcount fell 1,000, as job reductions more than offset the acquisition of 2,000-strong Flywheel, and the agency group ...

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

As advertisers pay more for an ever-scarcer supply of ratings points, pharma’s ironclad devotion to TV could finally be in ...

Pfizer announced Jeffrey Legos, PhD, MBA as its new chief oncology officer. Bluejay Therapeutics announced Mary Cromwell, PhD, has joined its leadership team as SVP and head of technical operations.

Weber Shandwick has promoted Kelley Yoder to lead its North America health practice, effective on Friday.

This renewed interest in DB presented Tarsus with an opportunity to reup its efforts to combat a pressing yet often overlooked health condition.

Kaiser Permanente has been under the microscope for shortcomings in mental health care, even as it is held in high esteem on the medical side.

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

Agencies told to restore public health websites; How Robert F. Kennedy Jr. could revive a dormant task force to scrutinize vaccine safety; CVS Health CEO under close eye from investors.

More than 60,000 people in the U.S. bleed to death every year from traumatic events like car crashes or gunshot wounds, or ...